Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Curis stock | 1.24

Own Curis stock in just a few minutes.

Posted

Fact checked

Curis, Inc is a biotechnology business based in the US. Curis shares (CRIS) are listed on the NASDAQ and all prices are listed in US Dollars. Curis employs 28 staff and has a trailing 12-month revenue of around USD$11.2 million.

How to buy shares in Curis

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Curis. Find the stock by name or ticker symbol: CRIS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Curis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.24, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Curis, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Curis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Curis's share price?

Since the stock market crash in March caused by coronavirus, Curis's share price has had significant negative movement.

Its last market close was USD$1.24, which is 12.68% down on its pre-crash value of USD$1.42 and 91.95% up on the lowest point reached during the March crash when the shares fell as low as USD$0.646.

If you had bought USD$1,000 worth of Curis shares at the start of February 2020, those shares would have been worth USD$431.02 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$789.81.

Curis share price

Use our graph to track the performance of CRIS stocks over time.

Curis shares at a glance

Information last updated 2020-10-20.
Latest market close USD$1.24
52-week range USD$0.62 - USD$2.6
50-day moving average USD$1.1303
200-day moving average USD$1.0744
Wall St. target price USD$4.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.913

Buy Curis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Curis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Curis price performance over time

Historical closes compared with the close of $1.24 from 2020-11-16

1 week (2020-11-17) -3.13%
1 month (2020-10-23) 7.83%
3 months (2020-08-25) 8.77%
6 months (2020-05-23) N/A
1 year (2019-11-25) -29.94%
2 years (2018-11-23) -0.80%
3 years (2017-11-24) 38.02%
5 years (2015-11-25) -54.91%

Curis financials

Revenue TTM USD$11.2 million
Gross profit TTM USD$-12,801,000
Return on assets TTM -35.64%
Return on equity TTM 0%
Profit margin -280.63%
Book value $-0.61
Market capitalisation USD$63.6 million

TTM: trailing 12 months

Shorting Curis shares

There are currently 287,283 Curis shares held short by investors – that's known as Curis's "short interest". This figure is 50.2% down from 576,669 last month.

There are a few different ways that this level of interest in shorting Curis shares can be evaluated.

Curis's "short interest ratio" (SIR)

Curis's "short interest ratio" (SIR) is the quantity of Curis shares currently shorted divided by the average quantity of Curis shares traded daily (recently around 513005.35714286). Curis's SIR currently stands at 0.56. In other words for every 100,000 Curis shares traded daily on the market, roughly 560 shares are currently held short.

However Curis's short interest can also be evaluated against the total number of Curis shares, or, against the total number of tradable Curis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Curis's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Curis shares in existence, roughly 10 shares are currently held short) or 0.006% of the tradable shares (for every 100,000 tradable Curis shares, roughly 6 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Curis.

Find out more about how you can short Curis stock.

Curis share dividends

We're not expecting Curis to pay a dividend over the next 12 months.

Have Curis's shares ever split?

Curis's shares were split on a 1:5 basis on 30 May 2018. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Curis shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Curis shares which in turn could have impacted Curis's share price.

Curis share price volatility

Over the last 12 months, Curis's shares have ranged in value from as little as $0.62 up to $2.6. A popular way to gauge a stock's volatility is its "beta".

CRIS.US volatility(beta: 2.1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Curis's is 2.0976. This would suggest that Curis's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Curis overview

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company also has a scientific collaboration with DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments for Fimepinostat in DLBCL and solid malignancies. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site